REFERENCES
1. Global tuberculosis report 2022. Geneva: World Health Organization;
2022.
2. Global tuberculosis report 2021. Geneva: World Health Organization;
2021 2021.
3. Sia JK, Rengarajan J. Immunology of Mycobacterium tuberculosis
Infections. Microbiol Spectr. 2019;7(4).
4. Cai L, Li Z, Guan X, Cai K, Wang L, Liu J, et al. The Research
Progress of Host Genes and Tuberculosis Susceptibility. Oxid Med Cell
Longev. 2019;2019:9273056.
5. Ogishi M, Yang R, Aytekin C, Langlais D, Bourgey M, Khan T, et al.
Inherited PD-1 deficiency underlies tuberculosis and autoimmunity in a
child. Nat Med. 2021;27(9):1646-54.
6. Encinales L, Zuniga J, Granados-Montiel J, Yunis M, Granados J,
Almeciga I, et al. Humoral immunity in tuberculin skin test anergy and
its role in high-risk persons exposed to active tuberculosis. Mol
Immunol. 2010;47(5):1066-73.
7. An HR, Bai XJ, Liang JQ, Wang T, Wang ZY, Xue Y, et al. The
relationship between absolute counts of lymphocyte subsets and clinical
features in patients with pulmonary tuberculosis. Clin Respir J.
2022;16(5):369-79.
8. Viana LA, Cristelli MP, Santos DW, Tavares MG, Dantas MTC, Felipe CR,
et al. Influence of epidemiology, immunosuppressive regimens, clinical
presentation, and treatment on kidney transplant outcomes of patients
diagnosed with tuberculosis: A retrospective cohort analysis. Am J
Transplant. 2019;19(5):1421-31.
9. Martin SJ, Sabina EP. Malnutrition and Associated Disorders in
Tuberculosis and Its Therapy. J Diet Suppl. 2019;16(5):602-10.
10. Morais-Papini TF, Coelho-Dos-Reis JGA, Wendling APB, do Vale
Antonelli LR, Wowk PF, Bonato VLD, et al. Systemic Immunological changes
in patients with distinct clinical outcomes during Mycobacterium
tuberculosis infection. Immunobiology. 2017;222(11):1014-24.
11. Shafey BE-B, Mohamed & Ezzat, Sherif & Attia, Mohamed. Role of
some T-lymphocyte subsets in assessment of treatment response in
tuberculous patients. Egyptian Journal of Chest Diseases and
Tuberculosis. 2015;70.
12. Levitte S, Adams KN, Berg RD, Cosma CL, Urdahl KB, Ramakrishnan L.
Mycobacterial Acid Tolerance Enables Phagolysosomal Survival and
Establishment of Tuberculous Infection In Vivo. Cell Host Microbe.
2016;20(2):250-8.
13. Mi J, Liang Y, Liang J, Gong W, Wang S, Zhang J, et al. The Research
Progress in Immunotherapy of Tuberculosis. Front Cell Infect Microbiol.
2021;11:763591.
14. Fatima S, Bhaskar A, Dwivedi VP. Repurposing Immunomodulatory Drugs
to Combat Tuberculosis. Front Immunol. 2021;12:645485.
15. Afkhami S, Villela AD, D’Agostino MR, Jeyanathan M, Gillgrass A,
Xing Z. Advancing Immunotherapeutic Vaccine Strategies Against Pulmonary
Tuberculosis. Front Immunol. 2020;11:557809.
16. Tait DR, Hatherill M, Van Der Meeren O, Ginsberg AM, Van Brakel E,
Salaun B, et al. Final Analysis of a Trial of M72/AS01(E) Vaccine to
Prevent Tuberculosis. N Engl J Med. 2019;381(25):2429-39.
17. Yang XY, Chen QF, Li YP, Wu SM. Mycobacterium vaccae as adjuvant
therapy to anti-tuberculosis chemotherapy in never-treated tuberculosis
patients: a meta-analysis. PLoS One. 2011;6(9):e23826.
18. Mwinga A, Nunn A, Ngwira B, Chintu C, Warndorff D, Fine P, et al.
Mycobacterium vaccae (SRL172) immunotherapy as an adjunct to standard
antituberculosis treatment in HIV-infected adults with pulmonary
tuberculosis: a randomised placebo-controlled trial. Lancet.
2002;360(9339):1050-5.
19. Sharma SK, Katoch K, Sarin R, Balambal R, Kumar Jain N, Patel N, et
al. Efficacy and Safety of Mycobacterium indicus pranii as an adjunct
therapy in Category II pulmonary tuberculosis in a randomized trial. Sci
Rep. 2017;7(1):3354.
20. Gillard P, Yang PC, Danilovits M, Su WJ, Cheng SL, Pehme L, et al.
Safety and immunogenicity of the M72/AS01E candidate tuberculosis
vaccine in adults with tuberculosis: A phase II randomised study.
Tuberculosis (Edinb). 2016;100:118-27.
21. Jenum S, Tonby K, Rueegg CS, Ruhwald M, Kristiansen MP, Bang P, et
al. A Phase I/II randomized trial of H56:IC31 vaccination and adjunctive
cyclooxygenase-2-inhibitor treatment in tuberculosis patients. Nat
Commun. 2021;12(1):6774.
22. Karbalaei Zadeh Babaki M, Soleimanpour S, Rezaee SA. Antigen 85
complex as a powerful Mycobacterium tuberculosis immunogene: Biology,
immune-pathogenicity, applications in diagnosis, and vaccine design.
Microb Pathog. 2017;112:20-9.
23. Liang Y, Wu X, Zhang J, Yang Y, Wang L, Bai X, et al. Treatment of
multi-drug-resistant tuberculosis in mice with DNA vaccines alone or in
combination with chemotherapeutic drugs. Scand J Immunol.
2011;74(1):42-6.
24. Liang Y, Wu X, Zhang J, Li N, Yu Q, Yang Y, et al. The treatment of
mice infected with multi-drug-resistant Mycobacterium tuberculosis using
DNA vaccines or in combination with rifampin. Vaccine.
2008;26(35):4536-40.
25. Okada M, Kita Y, Hashimoto S, Nakatani H, Nishimastu S, Kioka Y, et
al. Preclinical study and clinical trial of a novel therapeutic vaccine
against multi-drug resistant tuberculosis. Hum Vaccin Immunother.
2017;13(2):298-305.
26. Shi L, North R, Gennaro ML. Effect of growth state on transcription
levels of genes encoding major secreted antigens of Mycobacterium
tuberculosis in the mouse lung. Infect Immun. 2004;72(4):2420-4.
27. Rogerson BJ, Jung YJ, LaCourse R, Ryan L, Enright N, North RJ.
Expression levels of Mycobacterium tuberculosis antigen-encoding genes
versus production levels of antigen-specific T cells during stationary
level lung infection in mice. Immunology. 2006;118(2):195-201.
28. Liang Y, Wu X, Zhang J, Xiao L, Yang Y, Bai X, et al. Immunogenicity
and therapeutic effects of Ag85A/B chimeric DNA vaccine in mice infected
with Mycobacterium tuberculosis. FEMS Immunol Med Microbiol.
2012;66(3):419-26.
29. Babiuk S, Baca-Estrada ME, Foldvari M, Storms M, Rabussay D, Widera
G, et al. Electroporation improves the efficacy of DNA vaccines in large
animals. Vaccine. 2002;20(27-28):3399-408.
30. Tacket CO, Roy MJ, Widera G, Swain WF, Broome S, Edelman R. Phase 1
safety and immune response studies of a DNA vaccine encoding hepatitis B
surface antigen delivered by a gene delivery device. Vaccine.
1999;17(22):2826-9.
31. Liang Y, Cui L, Xiao L, Liu X, Yang Y, Ling Y, et al.
Immunotherapeutic Effects of Different Doses of Mycobacterium
tuberculosis ag85a/b DNA Vaccine Delivered by Electroporation.
Front Immunol. 2022;13:876579.
32. Gong WP, Liang Y, Ling YB, Zhang JX, Yang YR, Wang L, et al. Effects
of Mycobacterium vaccae vaccine in a mouse model of tuberculosis:
protective action and differentially expressed genes. Mil Med Res.
2020;7(1):25.
33. van den Berg RA, De Mot L, Leroux-Roels G, Bechtold V, Clement F,
Coccia M, et al. Adjuvant-Associated Peripheral Blood mRNA Profiles and
Kinetics Induced by the Adjuvanted Recombinant Protein Candidate
Tuberculosis Vaccine M72/AS01 in Bacillus Calmette-Guerin-Vaccinated
Adults. Front Immunol. 2018;9:564.
34. Martinez-Perez A, Estevez O, Gonzalez-Fernandez A. Contribution and
Future of High-Throughput Transcriptomics in Battling Tuberculosis.
Front Microbiol. 2022;13:835620.
35. Wu X, Li Q, Yang Y, Zhang C, Li J, Zhang J, et al. Latent
tuberculosis infection amongst new recruits to the Chinese army:
comparison of ELISPOT assay and tuberculin skin test. Clin Chim Acta.
2009;405(1-2):110-3.
36. Moreira-Teixeira L, Tabone O, Graham CM, Singhania A, Stavropoulos
E, Redford PS, et al. Mouse transcriptome reveals potential signatures
of protection and pathogenesis in human tuberculosis. Nat Immunol.
2020;21(4):464-76.
37. Domaszewska T, Scheuermann L, Hahnke K, Mollenkopf H, Dorhoi A,
Kaufmann SHE, et al. Concordant and discordant gene expression patterns
in mouse strains identify best-fit animal model for human tuberculosis.
Sci Rep. 2017;7(1):12094.
38. Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky
M, et al. NCBI GEO: archive for functional genomics data sets–update.
Nucleic Acids Res. 2013;41(Database issue):D991-5.
39. Beamer GL, Cyktor J, Flaherty DK, Stromberg PC, Carruthers B, Turner
J. CBA/J mice generate protective immunity to soluble Ag85 but fail to
respond efficiently to Ag85 during natural Mycobacterium tuberculosis
infection. Eur J Immunol. 2012;42(4):870-9.
40. Pabreja S, Garg T, Rath G, Goyal AK. Mucosal vaccination against
tuberculosis using Ag85A-loaded immunostimulating complexes. Artif Cells
Nanomed Biotechnol. 2016;44(2):532-9.
41. Meshkat Z, Teimourpour A, Rashidian S, Arzanlou M, Teimourpour R.
Immunogenicity of a DNA Vaccine Encoding Ag85a-Tb10.4 Antigens from
Mycobacterium Tuberculosis. Iran J Immunol. 2016;13(4):289-95.
42. Kalams SA, Parker SD, Elizaga M, Metch B, Edupuganti S, Hural J, et
al. Safety and comparative immunogenicity of an HIV-1 DNA vaccine in
combination with plasmid interleukin 12 and impact of intramuscular
electroporation for delivery. J Infect Dis. 2013;208(5):818-29.
43. Lee YH, Lim H, Lee JA, Kim SH, Hwang YH, In HJ, et al. Optimization
of Zika DNA vaccine by delivery systems. Virology. 2021;559:10-4.
44. Sheng Z, Gao N, Cui X, Fan D, Chen H, Wu N, et al. Electroporation
enhances protective immune response of a DNA vaccine against Japanese
encephalitis in mice and pigs. Vaccine. 2016;34(47):5751-7.
45. Best SR, Peng S, Juang CM, Hung CF, Hannaman D, Saunders JR, et al.
Administration of HPV DNA vaccine via electroporation elicits the
strongest CD8+ T cell immune responses compared to intramuscular
injection and intradermal gene gun delivery. Vaccine.
2009;27(40):5450-9.
46. Petkov S, Starodubova E, Latanova A, Kilpelainen A, Latyshev O,
Svirskis S, et al. DNA immunization site determines the level of gene
expression and the magnitude, but not the type of the induced immune
response. PLoS One. 2018;13(6):e0197902.
47. Chang SW, Pan WS, Lozano Beltran D, Oleyda Baldelomar L, Solano MA,
Tuero I, et al. Gut hormones, appetite suppression and cachexia in
patients with pulmonary TB. PLoS One. 2013;8(1):e54564.
48. Masters SL, Dunne A, Subramanian SL, Hull RL, Tannahill GM, Sharp
FA, et al. Activation of the NLRP3 inflammasome by islet amyloid
polypeptide provides a mechanism for enhanced IL-1beta in type 2
diabetes. Nat Immunol. 2010;11(10):897-904.
49. Morikawa S, Kaneko N, Okumura C, Taguchi H, Kurata M, Yamamoto T, et
al. IAPP/amylin deposition, which is correlated with expressions of ASC
and IL-1beta in beta-cells of Langerhans’ islets, directly initiates
NLRP3 inflammasome activation. Int J Immunopathol Pharmacol.
2018;32:2058738418788749.
50. Vogt AS, Roesti ES, Mohsen MO, Leonchiks A, Vogel M, Bachmann MF.
Anti-IAPP Monoclonal Antibody Improves Clinical Symptoms in a Mouse
Model of Type 2 Diabetes. Vaccines (Basel). 2021;9(11).
51. Gu HF. Genetic, Epigenetic and Biological Effects of Zinc
Transporter (SLC30A8) in Type 1 and Type 2 Diabetes. Curr Diabetes Rev.
2017;13(2):132-40.
52. Nayak DK, Calderon B, Vomund AN, Unanue ER. ZnT8-reactive T cells
are weakly pathogenic in NOD mice but can participate in diabetes under
inflammatory conditions. Diabetes. 2014;63(10):3438-48.
53. Sladek R, Rocheleau G, Rung J, Dina C, Shen L, Serre D, et al. A
genome-wide association study identifies novel risk loci for type 2
diabetes. Nature. 2007;445(7130):881-5.
54. Montero-Hadjadje M, Vaingankar S, Elias S, Tostivint H, Mahata SK,
Anouar Y. Chromogranins A and B and secretogranin II: evolutionary and
functional aspects. Acta Physiol (Oxf). 2008;192(2):309-24.
55. Shooshtarizadeh P, Zhang D, Chich JF, Gasnier C, Schneider F, Haikel
Y, et al. The antimicrobial peptides derived from
chromogranin/secretogranin family, new actors of innate immunity. Regul
Pept. 2010;165(1):102-10.
56. De Lorenzo R, Sciorati C, Ramirez GA, Colombo B, Lore NI, Capobianco
A, et al. Chromogranin A plasma levels predict mortality in COVID-19.
PLoS One. 2022;17(4):e0267235.
57. Hsu CH, Reyes LF, Orihuela CJ, Buitrago R, Anzueto A, Soni NJ, et
al. Chromogranin A levels and mortality in patients with severe sepsis.
Biomarkers. 2015;20(3):171-6.
58. Herold Z, Doleschall M, Kovesdi A, Patocs A, Somogyi A. Chromogranin
A and its role in the pathogenesis of diabetes mellitus. Endokrynol Pol.
2018;69(5):598-610.
59. Herold Z, Doleschall M, Somogyi A. Role and function of granin
proteins in diabetes mellitus. World J Diabetes. 2021;12(7):1081-92.
60. Li Y, Guo J, Xia T, Wu F, Tian J, Cheng M, et al. Incidence of
pulmonary tuberculosis in Chinese adults with type 2 diabetes: a
retrospective cohort study in Shanghai. Sci Rep. 2020;10(1):8578.
61. Azzopardi E, Lloyd C, Teixeira SR, Conlan RS, Whitaker IS. Clinical
applications of amylase: Novel perspectives. Surgery. 2016;160(1):26-37.
62. Prasad H, Ghetla SR, Butala U, Kesarkar A, Parab S. COVID-19 and
Serum Amylase and Lipase Levels. Indian J Surg. 2022:1-4.
63. Torrelles JB, Schlesinger LS. Integrating Lung Physiology,
Immunology, and Tuberculosis. Trends Microbiol. 2017;25(8):688-97.
64. Griese M. Pulmonary surfactant in health and human lung diseases:
state of the art. Eur Respir J. 1999;13(6):1455-76.
65. Cooney AL, Wambach JA, Sinn PL, McCray PB, Jr. Gene Therapy
Potential for Genetic Disorders of Surfactant Dysfunction. Front Genome
Ed. 2021;3:785829.
66. Gaynor CD, McCormack FX, Voelker DR, McGowan SE, Schlesinger LS.
Pulmonary surfactant protein A mediates enhanced phagocytosis of
Mycobacterium tuberculosis by a direct interaction with human
macrophages. J Immunol. 1995;155(11):5343-51.
67. Thorenoor N, Zhang X, Umstead TM, Scott Halstead E, Phelps DS,
Floros J. Differential effects of innate immune variants of surfactant
protein-A1 (SFTPA1) and SP-A2 (SFTPA2) in airway function after
Klebsiella pneumoniae infection and sex differences. Respir Res.
2018;19(1):23.
68. Sorensen GL, Husby S, Holmskov U. Surfactant protein A and
surfactant protein D variation in pulmonary disease. Immunobiology.
2007;212(4-5):381-416.
69. Zhao JW, Jiao L, Guo MM, Zheng L, Wang XB, Gao SH, et al. SFTPC
genetic polymorphisms are associated with tuberculosis susceptibility
and clinical phenotype in a Western Chinese Han population. Exp Ther
Med. 2020;20(5):100.
70. Thacker VV, Dhar N, Sharma K, Barrile R, Karalis K, McKinney JD. A
lung-on-chip model of early Mycobacterium tuberculosis infection reveals
an essential role for alveolar epithelial cells in controlling bacterial
growth. Elife. 2020;9.
71. Moliva JI, Duncan MA, Olmo-Fontanez A, Akhter A, Arnett E, Scordo
JM, et al. The Lung Mucosa Environment in the Elderly Increases Host
Susceptibility to Mycobacterium tuberculosis Infection. J Infect Dis.
2019;220(3):514-23.
72. Janssen R, Visser MPJ, Dofferhoff ASM, Vermeer C, Janssens W, Walk
J. Vitamin K metabolism as the potential missing link between lung
damage and thromboembolism in Coronavirus disease 2019. Br J Nutr.
2021;126(2):191-8.
73. Viegas CSB, Costa RM, Santos L, Videira PA, Silva Z, Araujo N, et
al. Gla-rich protein function as an anti-inflammatory agent in
monocytes/macrophages: Implications for calcification-related chronic
inflammatory diseases. PLoS One. 2017;12(5):e0177829.
74. Kaarteenaho-Wiik R, Soini Y. Claudin-1, -2, -3, -4, -5, and -7 in
usual interstitial pneumonia and sarcoidosis. J Histochem Cytochem.
2009;57(3):187-95.
75. Hashimoto R, Takahashi J, Shirakura K, Funatsu R, Kosugi K, Deguchi
S, et al. SARS-CoV-2 disrupts respiratory vascular barriers by
suppressing Claudin-5 expression. Sci Adv. 2022;8(38):eabo6783.
76. Kim BG, Lee PH, Lee SH, Baek AR, Park JS, Lee J, et al. Impact of
the Endothelial Tight Junction Protein Claudin-5 on Clinical Profiles of
Patients With COPD. Allergy Asthma Immunol Res. 2018;10(5):533-42.
77. Geng P, Ma T, Xing J, Jiang L, Sun H, Zhu B, et al. Dexamethasone
ameliorates H(2)S-induced acute lung injury by increasing claudin-5
expression via the PI3K pathway. Hum Exp Toxicol. 2018;37(6):626-35.
78. Zuniga MC, Raghuraman G, Hitchner E, Weyand C, Robinson W, Zhou W.
PKC-epsilon and TLR4 synergistically regulate resistin-mediated
inflammation in human macrophages. Atherosclerosis. 2017;259:51-9.
79. Nair MG, Du Y, Perrigoue JG, Zaph C, Taylor JJ, Goldschmidt M, et
al. Alternatively activated macrophage-derived RELM-alpha is a negative
regulator of type 2 inflammation in the lung. J Exp Med.
2009;206(4):937-52.
80. Wang J, Li P, Yu Y, Fu Y, Jiang H, Lu M, et al. Pulmonary
surfactant-biomimetic nanoparticles potentiate heterosubtypic influenza
immunity. Science. 2020;367(6480).
81. Denroche HC, Verchere CB. IAPP and type 1 diabetes: implications for
immunity, metabolism and islet transplants. J Mol Endocrinol.
2018;60(2):R57-R75.
82. Muntjewerff EM, Dunkel G, Nicolasen MJT, Mahata SK, van den Bogaart
G. Catestatin as a Target for Treatment of Inflammatory Diseases. Front
Immunol. 2018;9:2199.
83. Zeigerer A, Sekar R, Kleinert M, Nason S, Habegger KM, Muller TD.
Glucagon’s Metabolic Action in Health and Disease. Compr Physiol.
2021;11(2):1759-83.
84. Zhang S, Xiong H, Yang J, Yuan X. Pan-Cancer Analysis Reveals the
Multidimensional Expression and Prognostic and Immunologic Roles of
VSTM2L in Cancer. Front Mol Biosci. 2021;8:792154.
85. Deng T, Shen P, Li A, Zhang Z, Yang H, Deng X, et al. CCDC65 as a
new potential tumor suppressor induced by metformin inhibits activation
of AKT1 via ubiquitination of ENO1 in gastric cancer. Theranostics.
2021;11(16):8112-28.
86. Hegele RA, Ramdath DD, Ban MR, Carruthers MN, Carrington CV, Cao H.
Polymorphisms in PNLIP, encoding pancreatic lipase, and associations
with metabolic traits. J Hum Genet. 2001;46(6):320-4.
87. Esteghamat F, Broughton JS, Smith E, Cardone R, Tyagi T, Guerra M,
et al. CELA2A mutations predispose to early-onset atherosclerosis and
metabolic syndrome and affect plasma insulin and platelet activation.
Nat Genet. 2019;51(8):1233-43.
88. Bloomquist BT, Darlington DN, Mains RE, Eipper BA. RESP18, a novel
endocrine secretory protein transcript, and four other transcripts are
regulated in parallel with pro-opiomelanocortin in melanotropes. J Biol
Chem. 1994;269(12):9113-22.
89. Mulugeta S, Beers MF. Surfactant protein C: its unique properties
and emerging immunomodulatory role in the lung. Microbes Infect.
2006;8(8):2317-23.
90. Hawgood S. Surfactant protein B: structure and function. Biol
Neonate. 2004;85(4):285-9.
91. Haczku A. Protective role of the lung collectins surfactant protein
A and surfactant protein D in airway inflammation. J Allergy Clin
Immunol. 2008;122(5):861-79; quiz 80-1.
92. Forbes LR, Haczku A. SP-D and regulation of the pulmonary innate
immune system in allergic airway changes. Clin Exp Allergy.
2010;40(4):547-62.
93. Jianfeng W, Yutao W, Jianbin B. Indolethylamine-N-Methyltransferase
Inhibits Proliferation and Promotes Apoptosis of Human Prostate Cancer
Cells: A Mechanistic Exploration. Front Cell Dev Biol. 2022;10:805402.
94. Zhang Z, Zhang N, Yu J, Xu W, Gao J, Lv X, et al. The Role of
Podoplanin in the Immune System and Inflammation. J Inflamm Res.
2022;15:3561-72.
95. Nakajima K, Ono M, Radovic U, Dizdarevic S, Tomizawa SI, Kuroha K,
et al. Lack of whey acidic protein (WAP) four-disulfide core domain
protease inhibitor 2 (WFDC2) causes neonatal death from respiratory
failure in mice. Dis Model Mech. 2019;12(11).
96. Shan L, Kawakami T, Asano S, Noritake S, Yoshimoto D, Yamashita K,
et al. Inverse relationship between Sec14l3 mRNA/protein expression and
allergic airway inflammation. Eur J Pharmacol. 2009;616(1-3):293-300.
97. Shan L, Noritake S, Fujiwara M, Asano S, Yoshida-Noro C, Noro N, et
al. Sec14l3 is specifically expressed in mouse airway ciliated cells.
Inflammation. 2012;35(2):702-12.
98. Wang Z, An J, Zhu D, Chen H, Lin A, Kang J, et al. Periostin: an
emerging activator of multiple signaling pathways. J Cell Commun Signal.
2022;16(4):515-30.
99. Shultz MA, Morin D, Chang AM, Buckpitt A. Metabolic capabilities of
CYP2F2 with various pulmonary toxicants and its relative abundance in
mouse lung subcompartments. J Pharmacol Exp Ther. 2001;296(2):510-9.
100. Rump K, Unterberg M, Bergmann L, Bankfalvi A, Menon A, Schafer S,
et al. AQP5-1364A/C polymorphism and the AQP5 expression influence
sepsis survival and immune cell migration: a prospective laboratory and
patient study. J Transl Med. 2016;14(1):321.
101. Lin WC, Gowdy KM, Madenspacher JH, Zemans RL, Yamamoto K,
Lyons-Cohen M, et al. Epithelial membrane protein 2 governs
transepithelial migration of neutrophils into the airspace. J Clin
Invest. 2020;130(1):157-70.
102. Deguchi A, Tomita T, Omori T, Komatsu A, Ohto U, Takahashi S, et
al. Serum amyloid A3 binds MD-2 to activate p38 and NF-kappaB pathways
in a MyD88-dependent manner. J Immunol. 2013;191(4):1856-64.
103. Cai Y, Bolte C, Le T, Goda C, Xu Y, Kalin TV, et al. FOXF1
maintains endothelial barrier function and prevents edema after lung
injury. Sci Signal. 2016;9(424):ra40.
104. Garg M, Braunstein G, Koeffler HP. LAMC2 as a therapeutic target
for cancers. Expert Opin Ther Targets. 2014;18(9):979-82.
105. Schurgers LJ, Uitto J, Reutelingsperger CP. Vitamin K-dependent
carboxylation of matrix Gla-protein: a crucial switch to control ectopic
mineralization. Trends Mol Med. 2013;19(4):217-26.
106. Fu P, Yang Z, Bach LA. Prohibitin-2 binding modulates insulin-like
growth factor-binding protein-6 (IGFBP-6)-induced rhabdomyosarcoma cell
migration. J Biol Chem. 2013;288(41):29890-900.
107. Wang X, Cui H, Wu S. CTGF: A potential therapeutic target for
Bronchopulmonary dysplasia. Eur J Pharmacol. 2019;860:172588.
Table 1 The primer sequences for amplification of the DE genes